Arcutis Biotherapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ARQT, updated each market day.
ARQT AI Sentiment
AI sees no strong directional signal for Arcutis Biotherapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Arcutis Biotherapeutics, Inc. Common Stock
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Sector
Exchange
Market Cap
$2,859,174,472
Cap Tier
Employees
354
Headquarters
WESTLAKE VILLAGE, CA
Listed Since
Jan. 31, 2020
Website
ARQT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ARQT Volatility
Arcutis Biotherapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
